124 completed. 124 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 124 | Completed 124 |
| Phase 2 | 6 | Completed 6 |
Follow Chronic Obstructive Pulmonary Disease: new trials by email Literature Review of Chronic Obstructive Pulmonary Disease trials Research Report on Chronic Obstructive Pulmonary Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD Itepekimab (SAR440340), Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Sanofi | 669 | 2024-01-11 | 2026-09-18 |
| A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | AstraZeneca | 171 | 2023-10-24 | 2026-03-05 |
| A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Ensifentrine, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Nuance Pharma (shanghai) Co., Ltd | 526 | 2023-03-10 | 2025-06-04 |
| Comparison of Corticosteroids vs Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the ICU Methylprednisolone, Placebos - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Versailles Hospital | 440 | 2021-10-25 | 2026-10-23 |
| Functional Respiratory Imaging Study (DARWiIN) Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium (BDP/FF/GB) - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 25 | 2021-05-18 | 2026-04-09 |
| Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) Itepekimab SAR440340, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Sanofi | 1234 | 2021-02-12 | 2026-10-09 |
| Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) Itepekimab SAR440340, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Sanofi | 1127 | 2020-12-16 | 2026-10-15 |
| A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Ensifentrine, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 763 | 2020-09-29 | 2023-11-13 |
| A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Ensifentrine, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 790 | 2020-09-22 | 2023-10-16 |
| Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Sanofi | 935 | 2020-07-06 | 2025-05-29 |
| Preventing Adverse Cardiac Events in COPD Bisoprolol, Placebo Oral Tablet - Chronic Obstructive Pulmonary Disease, Cardiovascular Diseases | Phase 3 | Completed | The George Institute | 280 | 2020-06-30 | 2025-05-16 |
| Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations Benralizumab, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | AstraZeneca | 689 | 2019-08-26 | 2025-08-19 |
| The Anti-oxidant Effects of N-Acetylcysteine in Chronic Obstructive Pulmonary Disease (COPD) N-acetylcysteine - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Siriraj Hospital | 35 | 2019-05-01 | 2025-03-14 |
| Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Sanofi | 939 | 2019-04-15 | 2024-02-28 |
| Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN) CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo, Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 750 | 2018-07-30 | 2026-05-12 |
| Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness Placebo, Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®) - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Lupin, Inc. | 377 | 2017-11-21 | 2021-04-05 |
| Functional Respiratory Imaging Study (FRI) Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 20 | 2017-11-20 | 2020-03-04 |
| Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Albuterol sulfate (ABS) - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 405 | 2017-09-28 | 2021-11-09 |
| Short Antibiotic Treatment Versus Duration Guided by Markers of Inflammation in the Treatment of AECOPD Levofloxacin 500mg - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | University of Monastir | 310 | 2017-05-01 | 2020-11-10 |
| Breathlessness Exertion and Morphine Sulphate Placebo, Morphine Sulfate, Plus laxative (Docusate with senna) - Chronic Obstructive Pulmonary Disease, Dyspnea | Phase 3 | Completed | Flinders University | 171 | 2016-08-08 | 2020-02-11 |
Showing 20 of 124. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (124) · Bronchitis, Chronic (12) · Emphysema (12) · Lung Diseases (10) · Lung Diseases, Obstructive (9) · Dyspnea (5) · Motor Activity (3) · Respiratory Insufficiency (3) · Hypertension, Pulmonary (2) · Respiratory Tract Diseases (2) · Smoking (2) · Asthma (1) · Bronchiolitis (1) · Bronchitis (1) · Carcinoma, Non-Small-Cell Lung (1)
Chronic Disease (124) · Disease Attributes (124) · Pathologic Processes (124) · Pathological Conditions, Signs and Symptoms (124) · Respiratory Tract Diseases (122) · Lung Diseases, Obstructive (115) · Lung Diseases (114) · Infections (15) · Bronchial Diseases (14) · Respiratory Tract Infections (13) · Bronchitis (12) · Respiration Disorders (9) · Signs and Symptoms (7) · Signs and Symptoms, Respiratory (7) · Behavior (5)
Formoterol Fumarate (20) · Tiotropium Bromide (14) · Glycopyrrolate (13) · indacaterol (13) · Budesonide (9) · aclidinium bromide (8) · indacaterol-glycopyrronium combination (8) · Albuterol (7) · Salmeterol Xinafoate (6) · Budesonide, Formoterol Fumarate Drug Combination (5) · Roflumilast (5) · Beclomethasone (4) · Azithromycin (3) · Foster Home Care (3) · ensifentrine (3)
AstraZeneca (24) · Novartis Pharmaceuticals (20) · Chiesi Farmaceutici S.p.A. (8) · Novartis (8) · National Heart, Lung, and Blood Institute (NHLBI) (5) · Sanofi (5) · Sumitomo Pharma America, Inc. (5) · Dey (2) · Mundipharma Research Limited (2) · Pearl Therapeutics, Inc. (2) · United Christian Hospital (2) · University of Colorado, Denver (2) · University of Monastir (2) · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (2) · Wim Janssens (2)
United States (53) · Germany (28) · Hungary (26) · Canada (25) · Poland (23) · United Kingdom (23) · Spain (22) · France (19) · Italy (17) · South Korea (17) · Belgium (15) · Russia (15) · Czechia (14) · Denmark (14) · Netherlands (14)
Esther Garcia, MD (6) · Colin Reisner, MD (2) · John Connett (2) · Jorgen Vestbo, MD (2) · Nicholas Anthonisen (2) · William Vandivier, MD (2) · Wim Janssens, MD PhD (2) · Adrian R Martineau, MRCP (1) · Ajay Mahal, PhD (1) · Anne E Holland, PhD (1)
PMID 42551404, PMID 25670896, PMID 29331313, PMID 21272339, PMID 22003288, PMID 22177371, PMID 22206353, PMID 22383665, PMID 23020650, PMID 24156566, PMID 26024688, PMID 28419462, PMID 28993871, PMID 32021148, PMID 32450869, PMID 35815359, PMID 37364283, PMID 39106052, PMID 39197510, PMID 39854278, PMID 39894389, PMID 41794122, PMID 42153327, PMID 42337097, PMID 17290043, PMID 17711594, PMID 17908710, PMID 17962632, PMID 18535254, PMID 18535255, PMID 18641094, PMID 19228428, PMID 19232039, PMID 19537837, PMID 19716961, PMID 19882497, PMID 19910177, PMID 20018959, PMID 20102307, PMID 20211002, PMID 20214820, PMID 20522841, PMID 20536364, PMID 20860505, PMID 20965712, PMID 21227674, PMID 21397482, PMID 21498063, PMID 21622587, PMID 22033040
2009 (6), 2008 (2), 2018 (2), 2014 (1), 2017 (1), 2019 (1), 2023 (1), N01HR761971 (1), R01HL034019 (1), R01HL071022 (1), U01HL050267 (1)